Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Boehringer Ingelheim
McKinsey
Medtronic
AstraZeneca

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021902

See Plans and Pricing

« Back to Dashboard

NDA 021902 describes VEREGEN, which is a drug marketed by Fougera Pharms Inc and is included in one NDA. It is available from one supplier. There are four patents protecting this drug. Additional details are available on the VEREGEN profile page.

The generic ingredient in VEREGEN is sinecatechins. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the sinecatechins profile page.
Summary for 021902
Tradename:VEREGEN
Applicant:Fougera Pharms Inc
Ingredient:sinecatechins
Patents:4
Generic Entry Opportunity Date for 021902
Generic Entry Date for 021902*:
Constraining patent/regulatory exclusivity:
Dosage:
OINTMENT;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 021902
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VEREGEN sinecatechins OINTMENT;TOPICAL 021902 NDA PharmaDerm a division of Fougera Pharmaceuticals Inc. 10337-450 10337-450-03 1 TUBE in 1 CARTON (10337-450-03) > 30 g in 1 TUBE
VEREGEN sinecatechins OINTMENT;TOPICAL 021902 NDA PharmaDerm a division of Fougera Pharmaceuticals Inc. 10337-450 10337-450-08 1 TUBE in 1 CARTON (10337-450-08) > 2 g in 1 TUBE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:OINTMENT;TOPICALStrength15%
Approval Date:Oct 31, 2006TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Nov 18, 2022Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF GENITAL WARTS
Patent:  Start TrialPatent Expiration:Oct 31, 2020Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF GENITAL WARTS
Patent:  Start TrialPatent Expiration:Oct 2, 2026Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF GENITAL WARTS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Baxter
McKesson
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.